萊爾斯丹(00738.HK)年度虧損擴大8.87%至3051.9萬元
格隆匯5月25日丨萊爾斯丹(00738.HK)公佈,截至2020年2月29日止年度,公司實現收益人民幣7.36億元(單位下同),同比減少18.97%;毛利4.56億元,同比減少19.95%;公司權益持有人應占年度虧損3051.9萬元,同比擴大8.87%;每股基本虧損4.32分。
2019/20財政年度,受中美貿易摩擦影響,內地消費意慾減弱,加上新型冠狀病毒疫情於第四季度爆發,集團銷售同比及同店俱錄得負增長。由於銷售下跌及存貨撥備增加,全年毛利額同比下19.9%至人民幣4.56億元,毛利率較去年降低0.7個百分點至62.0%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.